

### **Amendments to the Claims:**

This listing of claims replaces all prior versions and listings of claims in the application.

### **Listing of Claims:**

1. (Original) An biodegradable barrier network, comprising:
  - a) a cationic polypeptide,
  - b) an anionic polypeptide and
  - c) a pharmaceutically acceptable carrier.
2. (Currently Amended) The biodegradable barrier network according to claim 1, wherein ~~a)~~ amino acid residues in the cationic polypeptide are selected from the group consisting of amino acid residues R, H, K, synthetic and semisynthetic variants and mixtures thereof.
3. (Currently Amended) The biodegradable barrier network according to claim 2, wherein ~~b)~~ amino acid residues in the anionic polypeptide are selected from the group consisting of the amino acid residues D, E, synthetic and semisynthetic variants and mixtures thereof.
4. (Currently Amended) The biodegradable barrier network according to claim 1, wherein the amino acid residues within at least one of the polypeptides are ~~comprise amino acid residues~~ of the same type.
5. (Previously Presented) The biodegradable barrier, network according to claim 1, wherein at least one of the polypeptides is linked to one or more amino acid residues, other peptides or other substances.
6. (Previously Presented) The biodegradable barrier network according to claim 1, wherein at least one of the peptides is modified by amidation, esterification, acylation, PEGylation or alkylation.
7. (Previously Presented) The biodegradable network according to claim 1, wherein the peptides have a size of at least 5.000 Da, such as from about 5.000 to about 50.000 Da.

8. (Previously Presented) The biodegradable barrier network according to claim 1, wherein the biodegradable network comprises a pharmaceutical acceptable carrier, such as a diluent or buffer.

9. (Previously Presented) The biodegradable barrier network according to claim 1, wherein the biodegradable network comprises a therapeutic agent such as antimicrobial agents, antiinflammatory agents, cleaning agents, antioxidants, apoptosis modulators, healing agents, fibrogenesis inhibitors, antitumor agents and antibleeding agents.

10. (Original) The biodegradable barrier network according to claim 9, wherein the therapeutic agent is selected from the group comprising of penicillins, cephalosporins, carbacephems, tetracyclines, macrolides, iodine, silver, copper, clorhexidine, acetylsalicylic acid, proteolytic enzymes, vitamins, glutathione, folic acid, curcumin, resveratrol, anthocyanidins, glucocorticosteroids, insulin, dexamethasone, carotenoids, linoleic and conjugated-linoleic acids, melatonin, isothiocyanates, shikonin, solamargine, perifosine, deoxynivalenol, carboxyamido-triazole (CAI), histone deacetylase inhibitors, growth factors, insulin, vitamin E, retinoic acid, herbal components norepinephrine, gelatin, collagen and oxidized cellulose.

11. (Original) An applicator comprising:

a) a cationic polypeptide and a pharmaceutically acceptable carrier;

b) an anionic polypeptide and a pharmaceutically acceptable carrier;

said cationic polypeptide and anionic polypeptide being separated from each other by a separator.

12. (Original) The applicator according to claim 11, wherein the applicator is selected from the group comprising of syringes, one or multi-component sprays, nebulators, plasters, catheters, adhesives, implants and bandages.

13. (Previously Presented) The applicator according to claim 11, wherein the separator is a gelled aqueous solution or a membrane.

14. (Cancel)

15. (Original) A kit comprising

a) a cationic polypeptide and a pharmaceutically acceptable carrier

- b) an anionic polypeptide and a pharmaceutically acceptable carrier and
- c) means for administering said cationic and anionic polypeptide.

16. (Cancel)

17. (Previously Presented) The kit according to claim 15, wherein the means is selected from the group comprising of syringes, plasters, catheters, adhesives, implants, bandages, one or multi-component sprays, and nebulators.

18. (Previously Presented) The applicator according to claim 11, comprising a therapeutic agent such as antimicrobial agents, antiinflammatory agents, cleaning agents, antioxidants, apoptosis modulators, healing agents, fibrogenesis inhibitors, antitumor agents and antibleeding agents.

19. (Previously Presented) The applicator or the kit according to claim 18, wherein the therapeutic agent is selected from the group comprising of penicillins, cephalosporins, carbacephems, tetracyclines, macrolides, iodine, silver, copper, clorhexidine, acetylsalicylic acid, proteolytic enzymes, vitamins, glutathione, folic acid, curcumin, resveratrol, epigallocatechin, anthocyanidins, glucocorticosteroids, insulin, dexamethasone, carotenoids, linoleic and conjugated-linoleic acids, melatonin, isothiocyanates, shikonin, solamargine, perifosine, deoxynivalenol, carboxyamido-triazole (CAI), histone deacetylase inhibitors, growth factors, insulin, vitamin E, retinoic acid, herbal components norepinephrine, gelatin, collagen and oxidized cellulose.

20. (Previously Presented) The applicator according to Claim 18, wherein the therapeutic agent is separated from the two polypeptides or mixed with one or both of the polypeptides.

21. (Cancel)

22. (Previously Presented) A method of treating a mammal having an injury, comprising use of the applicator according to claim 11 for creating the biodegradable barrier network.